

AMENDMENT NO. 1 TO MASTER CLINICAL STUDY AGREEMENT BETWEEN ASTRAZENECA AND UT SYSTEM INSTITUTIONS

This Amendment No. 1 to the Master Clinical Study Agreement between AstraZeneca LP/AstraZeneca Pharmaceuticals LP (AstraZeneca) and several institutions of The University of Texas System (“Amendment #1”) is made and entered into as of September 1, 2017 by and between AstraZeneca and the following member institutions (each an “Institution” or collectively, “Institutions”) of the University of Texas System (“UT System”): The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at Tyler, The University of Texas Medical Branch at Galveston, The University of Texas Southwestern Medical Center, The University of Texas at Austin.

RECITALS

A. AstraZeneca and the following member Institutions of The University of Texas System entered into a certain Master Clinical Study Agreement having an Effective Date of March 16, 2015 (the “Master Agreement”): The University of Texas Health Science Center at San Antonio, The University of Texas Health Science Center at Houston, The University of Texas Health Science Center at Tyler, The University of Texas Medical Branch at Galveston, The University of Texas Southwestern Medical Center, The University of Texas at Austin.

B. AstraZeneca and Institutions wish to amend the terms of the Master Agreement to specifically add another member institution of UT System, The University of Texas Rio Grande Valley, as a party to the Master Agreement. Additionally, Institutions also wish to amend the Master Agreement to add Clinical Trials Xpress, a wholly-owned initiative of UT System as further described below.

NOW, THEREFORE, it is hereby agreed as follows:

1. Section 2 of the Preamble is hereby amended to add Clinical Trials Xpress, An Initiative of The University of Texas System and The University of Texas Rio Grande Valley as Parties to the Master Agreement.
2. Additionally, Section 2 of the Preamble is hereby amended to revise the address for UT System by replacing “201” West 7th Street with “**210**” West 7th Street.
3. Article 2 Conduct of the Study is hereby amended to add a **new subsection 2.7** with the following text:

2.7 Clinical Trials Xpress (“CTX”) [www.clinicaltrialsxpress.org], a wholly-owned initiative of UT System, is the central coordinating office and team established to promote efficient and streamlined study start-up processes of multi-institutional clinical trials. The Clinical Trials Xpress network operating model accelerates study implementation by negotiating a single, common clinical trial study budget; using pre-

approved master clinical trial agreements and by adopting the UT System IRB Reciprocity model or central IRBs for regulatory oversight. Additionally, AstraZeneca may engage the services of the Clinical Trials Xpress central coordinating office when the applicable Study contemplated by this Master Agreement will be considered for participation by more than one Institution. As such, a separate Addendum (referenced in Section 2.3 above) between AstraZeneca and Clinical Trials Xpress may be entered into for the services Clinical Trials Xpress provides to AstraZeneca when more than one Institution is participating in a Study under this Master Agreement.

4. The signature blocks shall be amended to add a signature block for both Clinical Trials Xpress and The University of Texas Rio Grande Valley.
5. Appendix 4 is deleted in its entirety and hereby replaced with the attached revised and updated Appendix 4.
6. Except as expressly provided in this Amendment #1, all other terms, conditions and provisions of the Master Agreement shall continue in full force and effect as provided therein.

Remainder of this page is intentionally left blank

Signature Page Follows

THIS AMENDMENT #1 IS EXECUTED by the authorized representatives of AstraZeneca and the Institutions as of the dates indicated below.

SIGNED for and on behalf of

**AstraZeneca Pharmaceuticals LP and
AstraZeneca LP**

DocuSigned by:
Lori Russo

Signature

Name: Lori Russo

Title: US Contract & Budget Mgmt Ldr

Date: 02 November 2017

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Houston**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Tyler**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas System

Raymond S. Greenberg

Signature

Name: *Raymond S. Greenberg, MD, PhD*

Title: *Executive Vice Chancellor
for Health Affairs*

Date: *11-1-2017*

SIGNED for and on behalf of

**The University of Texas Health Science Center
at San Antonio**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Medical
Branch at Galveston**

Signature

Name:

Title:

Date:

THIS AMENDMENT #1 IS EXECUTED by the authorized representatives of AstraZeneca and the Institutions as of the dates indicated below.

SIGNED for and on behalf of

**AstraZeneca Pharmaceuticals LP and
AstraZeneca LP**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas System

Signature


Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Houston**



Signature

Name: *Kathleen M. Kreidler*

Title: *Assoc. V.P., Sponsored Projects*

Date: *11/1/2017*

SIGNED for and on behalf of

**The University of Texas Health Science Center
at San Antonio**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Tyler**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Medical
Branch at Galveston**

Signature

Name:

Title:

Date:

THIS AMENDMENT #1 IS EXECUTED by the authorized representatives of AstraZeneca and the Institutions as of the dates indicated below.

SIGNED for and on behalf of

**AstraZeneca Pharmaceuticals LP and
AstraZeneca LP**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas System

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Houston**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health Science Center
at San Antonio**

Chris G. Green

Signature

Name:

Chris G. Green, CPA

Title:

Director, Office of Sponsored Programs

Date:

10-23-17

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Tyler**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Medical
Branch at Galveston**

Signature

Name:

Title:

Date:

THIS AMENDMENT #1 IS EXECUTED by the authorized representatives of AstraZeneca and the Institutions as of the dates indicated below.

SIGNED for and on behalf of

**AstraZeneca Pharmaceuticals LP and
AstraZeneca LP**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas System

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Houston**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health Science Center
at San Antonio**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Tyler**

Signature

Name: *David Anderson*

Title: *Director, Sponsored Programs*

Date: *10/24/2017*

SIGNED for and on behalf of

**The University of Texas Medical
Branch at Galveston**

Signature

Name:

Title:

Date:

THIS AMENDMENT #1 IS EXECUTED by the authorized representatives of AstraZeneca and the Institutions as of the dates indicated below.

SIGNED for and on behalf of

**AstraZeneca Pharmaceuticals LP and
AstraZeneca LP**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas System

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Houston**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health Science Center
at San Antonio**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Health
Science Center at Tyler**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Medical
Branch at Galveston**



Signature

Name: Lori Simon

Title: Director, Office of Clinical Research

Date: 31 October 2017

SIGNED for and on behalf of

**The University of Texas Southwestern
Medical Center**

DocuSigned by:

Michael Serber

AS

Signature

Name: Michael Serber

Title: Vice President for Financial Affairs

Date: 10/24/2017 | 11:33 AM CDT

SIGNED for and on behalf of

**The University of Texas Rio Grande
Valley**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas at Austin

Bill Catlett

Signature

Name: Bill Catlett

Title: Director, Office of Industry Engagement

Date: 23 OCT 17

SIGNED for and on behalf of

**Clinical Trials Xpress
An Initiative of The University of
Texas System**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Southwestern
Medical Center**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

The University of Texas at Austin


Signature

Name: Bill Catlett

Title: Director, Office of Industry Engagement

Date: 23 OCT 17

SIGNED for and on behalf of

**The University of Texas Rio Grande
Valley**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**Clinical Trials Xpress
An Initiative of The University of
Texas System**

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Southwestern
Medical Center**

Signature


Name:

Title:

Date:

SIGNED for and on behalf of

**The University of Texas Rio Grande
Valley**



Signature

Name: Juan M. Sanchez, Ph.D.

Title: Interim Sr. Vice President for Research

Date: October 23, 2017

SIGNED for and on behalf of

The University of Texas at Austin

Signature

Name:

Title:

Date:

SIGNED for and on behalf of

**Clinical Trials Xpress
An Initiative of The University of
Texas System**



Signature

Name: Raymond S. Greenberg, MD, PhD

Title: Executive Vice Chancellor
For Health Affairs

Date: 11-1-2017

Appendix 4

Administrative Contact Person and Address for Each Institution

<p>David Hawkins Associate Director, Office of Sponsored Projects The University of Texas at Austin P.O. Box 7726 Austin, Texas 78713-7726 Phone: 512-471-6424 Fax: 512-471-6564 Email: dhawkins@austin.utexas.edu Tax ID: 74-600023</p>	<p>Arriel Stevens Sponsored Programs Administrator The University of Texas Southwestern Medical Center 5323 Harry Hines Blvd. Dallas, TX 75390-9105 Phone: 214-648-4139 Fax: 214-648-4474 Email: arriel.stevens@UTSouthwestern.edu Tax ID: 75-6002868</p>
<p>Chris G. Green, CPA Director, Office of Sponsored Programs The University of Texas Health Science Center at San Antonio 7703 Floyd Curl Dr, Mail Code 7828 San Antonio, TX 78229-3900 Phone: 210-567-2340 Fax: 210-567-8107 Email: contracts@uthscsa.edu Tax ID: 74-1586031</p>	<p>Kathleen Kreidler Associate Vice President, Sponsored Projects The University of Texas Health Science Center at Houston 7000 Fannin Street, UCT1006 Houston, TX 77030 Phone: 713-500-3999 Fax: 713-383-3746 Email: Kathleen.Kreidler@uth.tmc.edu Tax ID: 74-1761309</p> <p><i>Overnight address is:</i> 7000 Fannin Street, Suite UCT 1007-2 Houston, TX 77030</p>
<p>David Anderson Director, Office of Pre-Award Services The University of Texas Health Science Center at Tyler 11937 U.S. Hwy. 271 Tyler, TX 75708-3154 Phone: 903-877-7486 Fax: 903-877-7558 Email: david.anderson@uthct.edu Tax ID: 75-6001354</p>	<p>Toni D'Agostino Associate VP for Research, Office of Sponsored Projects The University of Texas Medical Branch at Galveston 301 University Boulevard 4.40 Rebecca Sealy Hospital Galveston, TX 77555-0156 Phone: 409-266-9413 Fax: 409-266-9469 Email: todayagost@utmb.edu Tax ID: 74-6000949</p>
<p>Rita Garza Interim Executive Director for the Office of Sponsored Programs; Office of the Senior VP for Research, Innovation, and Economic Development The University of Texas Rio Grande Valley 1201 West University Drive Edinburg, TX 78539 Phone: 965-665-3002 Fax: 956-665-2940 Email: spnpro@utrgv.edu Tax ID: 46-5292740</p>	<p>BethLynn Maxwell, Ph.D., J.D. Chief Health Research Officer and Associate General Counsel, Office of Health Affairs and Office of General Counsel The University of Texas System 210 West 7th Street Austin, TX 78701 Phone: 512-499-4518 Fax: 512-499-4523 Email: bmaxwell@utsystem.edu</p> <p>This will be the same contact information for Clinical Trials Xpress, An Initiative of The University of Texas System</p>